Phreesia (NYSE:PHR) Lowered to “Hold” Rating by Barclays

Barclays lowered shares of Phreesia (NYSE:PHR) from a strong-buy rating to a hold rating in a research note issued to investors on Thursday morning,Zacks.com reports.

Several other research firms have also issued reports on PHR. BMO Capital Markets lowered their price target on shares of Phreesia from $32.00 to $14.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 31st. Needham & Company LLC reduced their price target on Phreesia from $35.00 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. KeyCorp reduced their price target on Phreesia from $15.00 to $12.00 and set an “overweight” rating for the company in a research report on Monday, April 13th. Robert W. Baird reiterated a “neutral” rating and issued a $10.00 price target (down from $25.00) on shares of Phreesia in a research report on Tuesday, March 31st. Finally, Citigroup reiterated a “neutral” rating and issued a $10.00 price target (down from $25.00) on shares of Phreesia in a research report on Tuesday, March 31st. Eleven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Phreesia currently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Phreesia Stock Performance

NYSE PHR opened at $8.78 on Thursday. The company’s 50 day moving average is $9.94 and its 200-day moving average is $14.53. Phreesia has a 12-month low of $7.77 and a 12-month high of $32.76. The company has a quick ratio of 1.53, a current ratio of 1.53 and a debt-to-equity ratio of 0.41. The firm has a market cap of $533.29 million, a P/E ratio of 292.57 and a beta of 0.89.

Phreesia (NYSE:PHR) last posted its quarterly earnings results on Monday, March 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.05). Phreesia had a net margin of 0.48% and a return on equity of 3.23%. The business had revenue of $127.07 million during the quarter, compared to the consensus estimate of $126.75 million. During the same period last year, the firm earned ($0.11) EPS. The business’s revenue for the quarter was up 15.9% on a year-over-year basis. Sell-side analysts predict that Phreesia will post 0.28 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Yvonne Hui sold 10,063 shares of the business’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $9.08, for a total transaction of $91,372.04. Following the completion of the transaction, the insider directly owned 25,991 shares in the company, valued at $235,998.28. The trade was a 27.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Allison C. Hoffman sold 14,483 shares of the business’s stock in a transaction dated Friday, April 10th. The stock was sold at an average price of $8.07, for a total value of $116,877.81. Following the transaction, the general counsel owned 163,485 shares of the company’s stock, valued at approximately $1,319,323.95. The trade was a 8.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 50,493 shares of company stock valued at $461,983 in the last ninety days. 5.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Phreesia

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. grew its position in Phreesia by 2.7% during the second quarter. Raymond James Financial Inc. now owns 14,049 shares of the company’s stock worth $400,000 after buying an additional 375 shares in the last quarter. Alliancebernstein L.P. grew its position in Phreesia by 1.3% during the third quarter. Alliancebernstein L.P. now owns 62,712 shares of the company’s stock worth $1,475,000 after buying an additional 812 shares in the last quarter. Van ECK Associates Corp grew its position in Phreesia by 78.7% during the fourth quarter. Van ECK Associates Corp now owns 2,502 shares of the company’s stock worth $42,000 after buying an additional 1,102 shares in the last quarter. Arizona State Retirement System grew its position in Phreesia by 8.1% during the third quarter. Arizona State Retirement System now owns 17,608 shares of the company’s stock worth $414,000 after buying an additional 1,313 shares in the last quarter. Finally, Federated Hermes Inc. purchased a new position in Phreesia during the third quarter worth about $32,000. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

More Phreesia News

Here are the key news stories impacting Phreesia this week:

• Negative Sentiment: Multiple law firms, including Rosen Law Firm, Faruqi & Faruqi, Pomerantz, Bragar Eagel & Squire, Gross Law Firm, Robbins LLP, and Gainey McKenna & Egleston, announced or promoted class-action lawsuits against Phreesia, alleging potential securities fraud tied to the period from May 8, 2025 through March 30, 2026. Article Title
• Negative Sentiment: The lawsuits and related investor alerts may increase legal costs, management distraction, and uncertainty around prior disclosures, which can weigh on investor sentiment toward the stock. Article Title
• Neutral Sentiment: Phreesia’s latest quarterly results were mixed: revenue came in slightly above expectations, but EPS missed consensus, which may still be influencing how investors view the company’s fundamentals.
• Neutral Sentiment: Despite the recent news flow, analysts previously remained constructive overall, with several Buy/Outperform ratings and a median price target above the current share price, suggesting some longer-term optimism remains.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.